This Article Full Text Full Text (PDF) All Versions of this Article: 1535-7163.MCT-06-0746v1 6/9/2600    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bowers, R. K. Articles by Thomas, J. E. Search for Related Content PubMed PubMed Citation Articles by Bowers, R. K. Articles by Thomas, J. E.

Research Articles: Therapeutics, Targets, and Development

A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy

Lilly Research Laboratories, Indianapolis, Indiana

Requests for reprints: Rita K. Bowers, Lilly Corporate Center, Indianapolis, IN 46285. Phone: 317-433-6102; Fax: 317-277-2934. E-mail: bowers_rita_k{at}lilly.com

Abstract

Thrombin cleavages of selective proteinase-activated receptors (PAR) as well as PAR-activating peptide ligands can initiate the phosphoinositide 3-kinase (PI3K) signaling cascade in platelets. Downstream to this event, fibrinogen receptors on platelets undergo conformational changes that enhance fibrinogen binding. In our study, we used this phenomenon as a surrogate biomarker for assessing effects on PI3K activity. Our method, using flow cytometric measurement of fluorescent ligand and antibody binding, uncovered a 16- to 45-fold signal window after PAR-induced platelet activation. Pretreatment (in vitro) with the PI3K inhibitors wortmannin and LY294002 resulted in concentration-dependent inhibition at predicted potencies. In addition, platelets taken from mice treated with wortmannin were blocked from PAR-induced ex vivo activation concomitantly with a decrease in phosphorylation of AKT from excised tumor xenografts. This surrogate biomarker assay was successfully tested (in vitro) on blood specimens received from volunteer cancer patients. Our results indicate that measurement of platelet activation could serve as an effective drug activity biomarker during clinical evaluation of putative PI3K inhibitors. [Mol Cancer Ther 2007;6(9):2600–7]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/ 7/06; revised 6/11/07; accepted 8/ 1/07.